You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Treatment of Proliferative Vitreoretinopathy using Aerosolized Methotrexate

    SBC: POWERSCOPE, INC            Topic: NEI

    Project Summary Proliferative vitreoretinopathy (PVR) is a major complication of retinal detachments and is responsible for most of the failures in retinal reattachment surgeries. About 10% of retinal detachment patients suffer from PVR. These patients often have poor visual outcome despite multiple surgeries. Our previous work on inhibition of PVR has focused on pharmacological intervention concu ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBC: POP Biotechnologies Inc.            Topic: 102

    SUMMARY Our goal is to advance the commercialization of interstitial chemo-phototherapy (I-CPT) as a potent antitumor therapeutic option for locally advanced tumors. This application will focus on providing a proof of concept for the benefit of I-CPT in the treatment locally advanced hepatocellular carcinoma (HCC). Patients with inoperable locally advanced HCC have a poor prognosis with a 5-year s ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Enabling comprehensive diagnosis of sub-acute infection in chronic respiratory disease via high sensitivity next generation sequencing

    SBC: PEAK DIAGNOSTIC PARTNERS LLC            Topic: NIAID

    ABSTRACT Sub-acute lung infections are increasingly recognized as drivers of poor symptom control among a subset of individuals with chronic lung disease (estimated more than 2 million for Asthma and COPD patients). When these sub-acute infections are diagnosed and treated appropriately, chronic lung disease patients can convert from moderate/severe to a milder disease phenotype, requiring lower m ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy

    SBC: ENDECTRA, LLC            Topic: 102

    PROJECT SUMMARY Understanding of tumor molecular characteristics during a course of radiotherapy (RT) treatment is crucial to assess the efficacy of the treatment and adapt radiation dosage to optimize outcomes. Unfortunately, this cannot be routinely achieved by current diagnostic nuclear imaging modalities due to complex logistics and prohibitive costs. Alternatively, Cerenkov Emission (CE) is a ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System

    SBC: Marblehead Medical LLC            Topic: NHLBI

    PROJECT SUMMARYCarotid Artery Stenting (CAS) using embolic protection represents the current standard of care for patients with carotid artery stenosis considered at high risk for carotid endarterectomy. Distal filter devices are the most widely used protection devices, but these must be navigated through plaque prior to deployment, presenting a significant embolic risk. Strong evidence indicates ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL

    SBC: Actinium Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. FES-Rowing: Preventing the Secondary Conditions of Paralysis Through Vigorous Exercise

    SBC: Myolyn, LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT Lack of exercise is a major cause of secondary health conditions, especially for people with paralysis, for whom participation in physical activity is especially difficult. Hybrid functional electrical stimulation (H- FES) exercise enables vigorous, total body physical activity for people with paralysis. However, existing H-FES devices are neither affordable nor accessible ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Non-Invasive Oropharynx Appliance to Maintain Airway Patency

    SBC: ANEMED LLC            Topic: NHLBI

    Obstructive Sleep Apnea (OSA) is a serious condition that affects about 4% of the population. During sleep, the tongue can fall into the oropharynx and occlude the airways Patients with this condition suffer many instances of apneas (complete cessation of breathing) and hypopneas (period of abnormally low respiratory rate). The apnea- hypopnea index (AHI) gives the number of such episodes per hour ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels

    SBC: Photosonox LLC            Topic: NEI

    ABSTRACT / PROJECT SUMMARY Wet age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, up to 50% of patients in the long term have a suboptimal response to anti-VEGF therapy. A better alternative method for treatment of AMD is urgently needed. We have recently inve ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. An adjuvanted influenza vaccine platform for dose sparing, multiplexing, and rapid deployment

    SBC: POP Biotechnologies Inc.            Topic: NIAID

    Abstract Influenza is the cause of considerable morbidity and mortality globally. Certain groups, i.e., infants, pregnant young women, and older adults are especially at risk for severe disease. Despite immunization being the most effective and economical prophylactic approach, vaccines often provide less than optimal defense against an influenza illness, with efficacies ranging from 10-60%. This ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government